Earnings Feed
Start Free
Home/Filings/4/0001209191-14-060548
4//SEC Filing

Vitae Pharmaceuticals, Inc 4

Accession 0001209191-14-060548

CIK 0001157602operating
View on SEC.govCompany Profile

Filed

Sep 30, 8:00 PM ET

Accepted

Oct 1, 4:31 PM ET

Size

52.0 KB

Accession

0001209191-14-060548

Insider Transaction Report

Form 4
Period: 2014-09-29
Vitae Pharmaceuticals, IncVTAE
VENROCK ASSOCIATES
10% Owner
Transactions
  • Conversion

    Series B Preferred Stock

    2014-09-29−1,009,414→ 0 total(indirect: See Footnote)
    → Common Stock (1,009,414 underlying)
  • Conversion

    Common Stock

    2014-09-29+41,270→ 1,265,504 total(indirect: See Footnote)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−32,086→ 0 total(indirect: See Footnote)
    → Common Stock (48,333 underlying)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−3,563→ 0 total(indirect: See Footnote)
    → Common Stock (5,367 underlying)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+139,019$1,112,152→ 423,754 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+617,868$4,942,944→ 1,883,372 total(indirect: See Footnote)
  • Conversion

    Series B Preferred Stock

    2014-09-29−25,233→ 0 total(indirect: See Footnote)
    → Common Stock (25,233 underlying)
  • Conversion

    Common Stock

    2014-09-29+5,367→ 5,367 total(indirect: See Footnote)
  • Conversion

    Series B Preferred Stock

    2014-09-29−227,117→ 0 total(indirect: See Footnote)
    → Common Stock (227,117 underlying)
  • Conversion

    Common Stock

    2014-09-29+48,333→ 48,333 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+214,820→ 214,820 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+25,233→ 30,600 total(indirect: See Footnote)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−142,607→ 0 total(indirect: See Footnote)
    → Common Stock (214,820 underlying)
  • Conversion

    Series C Preferred Stock

    2014-09-29−9,285→ 0 total(indirect: See Footnote)
    → Common Stock (9,285 underlying)
  • Conversion

    Common Stock

    2014-09-29+1,009,414→ 1,224,234 total(indirect: See Footnote)
  • Conversion

    Series C Preferred Stock

    2014-09-29−41,270→ 0 total(indirect: See Footnote)
    → Common Stock (41,270 underlying)
  • Conversion

    Series C Preferred Stock

    2014-09-29−1,031→ 0 total(indirect: See Footnote)
    → Common Stock (1,031 underlying)
  • Conversion

    Common Stock

    2014-09-29+227,117→ 275,450 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+9,285→ 284,735 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+15,446$123,568→ 47,077 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+1,031→ 31,631 total(indirect: See Footnote)
VENROCK ENTREPRENEURS FUND III LP
10% Owner
Transactions
  • Conversion

    Common Stock

    2014-09-29+41,270→ 1,265,504 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+1,009,414→ 1,224,234 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+227,117→ 275,450 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+9,285→ 284,735 total(indirect: See Footnote)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−32,086→ 0 total(indirect: See Footnote)
    → Common Stock (48,333 underlying)
  • Conversion

    Series B Preferred Stock

    2014-09-29−25,233→ 0 total(indirect: See Footnote)
    → Common Stock (25,233 underlying)
  • Conversion

    Common Stock

    2014-09-29+214,820→ 214,820 total(indirect: See Footnote)
  • Conversion

    Series C Preferred Stock

    2014-09-29−41,270→ 0 total(indirect: See Footnote)
    → Common Stock (41,270 underlying)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+139,019$1,112,152→ 423,754 total(indirect: See Footnote)
  • Conversion

    Series B Preferred Stock

    2014-09-29−227,117→ 0 total(indirect: See Footnote)
    → Common Stock (227,117 underlying)
  • Conversion

    Common Stock

    2014-09-29+5,367→ 5,367 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+15,446$123,568→ 47,077 total(indirect: See Footnote)
  • Conversion

    Series C Preferred Stock

    2014-09-29−1,031→ 0 total(indirect: See Footnote)
    → Common Stock (1,031 underlying)
  • Conversion

    Series B Preferred Stock

    2014-09-29−1,009,414→ 0 total(indirect: See Footnote)
    → Common Stock (1,009,414 underlying)
  • Conversion

    Common Stock

    2014-09-29+25,233→ 30,600 total(indirect: See Footnote)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−142,607→ 0 total(indirect: See Footnote)
    → Common Stock (214,820 underlying)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−3,563→ 0 total(indirect: See Footnote)
    → Common Stock (5,367 underlying)
  • Conversion

    Common Stock

    2014-09-29+48,333→ 48,333 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+1,031→ 31,631 total(indirect: See Footnote)
  • Conversion

    Series C Preferred Stock

    2014-09-29−9,285→ 0 total(indirect: See Footnote)
    → Common Stock (9,285 underlying)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+617,868$4,942,944→ 1,883,372 total(indirect: See Footnote)
VEF MANAGEMENT III LLC
10% Owner
Transactions
  • Conversion

    Common Stock

    2014-09-29+214,820→ 214,820 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+48,333→ 48,333 total(indirect: See Footnote)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−32,086→ 0 total(indirect: See Footnote)
    → Common Stock (48,333 underlying)
  • Conversion

    Common Stock

    2014-09-29+9,285→ 284,735 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+1,031→ 31,631 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+139,019$1,112,152→ 423,754 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+617,868$4,942,944→ 1,883,372 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+15,446$123,568→ 47,077 total(indirect: See Footnote)
  • Conversion

    Series B Preferred Stock

    2014-09-29−25,233→ 0 total(indirect: See Footnote)
    → Common Stock (25,233 underlying)
  • Conversion

    Series C Preferred Stock

    2014-09-29−41,270→ 0 total(indirect: See Footnote)
    → Common Stock (41,270 underlying)
  • Conversion

    Series C Preferred Stock

    2014-09-29−1,031→ 0 total(indirect: See Footnote)
    → Common Stock (1,031 underlying)
  • Conversion

    Common Stock

    2014-09-29+5,367→ 5,367 total(indirect: See Footnote)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−142,607→ 0 total(indirect: See Footnote)
    → Common Stock (214,820 underlying)
  • Conversion

    Series B Preferred Stock

    2014-09-29−1,009,414→ 0 total(indirect: See Footnote)
    → Common Stock (1,009,414 underlying)
  • Conversion

    Common Stock

    2014-09-29+1,009,414→ 1,224,234 total(indirect: See Footnote)
  • Conversion

    Series B Preferred Stock

    2014-09-29−227,117→ 0 total(indirect: See Footnote)
    → Common Stock (227,117 underlying)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−3,563→ 0 total(indirect: See Footnote)
    → Common Stock (5,367 underlying)
  • Conversion

    Common Stock

    2014-09-29+227,117→ 275,450 total(indirect: See Footnote)
  • Conversion

    Series C Preferred Stock

    2014-09-29−9,285→ 0 total(indirect: See Footnote)
    → Common Stock (9,285 underlying)
  • Conversion

    Common Stock

    2014-09-29+25,233→ 30,600 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+41,270→ 1,265,504 total(indirect: See Footnote)
VENROCK MANAGEMENT III LLC
10% Owner
Transactions
  • Conversion

    Common Stock

    2014-09-29+1,009,414→ 1,224,234 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+1,031→ 31,631 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+5,367→ 5,367 total(indirect: See Footnote)
  • Conversion

    Series C Preferred Stock

    2014-09-29−9,285→ 0 total(indirect: See Footnote)
    → Common Stock (9,285 underlying)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+617,868$4,942,944→ 1,883,372 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+25,233→ 30,600 total(indirect: See Footnote)
  • Conversion

    Series C Preferred Stock

    2014-09-29−1,031→ 0 total(indirect: See Footnote)
    → Common Stock (1,031 underlying)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+15,446$123,568→ 47,077 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+214,820→ 214,820 total(indirect: See Footnote)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−142,607→ 0 total(indirect: See Footnote)
    → Common Stock (214,820 underlying)
  • Conversion

    Series B Preferred Stock

    2014-09-29−25,233→ 0 total(indirect: See Footnote)
    → Common Stock (25,233 underlying)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+139,019$1,112,152→ 423,754 total(indirect: See Footnote)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−32,086→ 0 total(indirect: See Footnote)
    → Common Stock (48,333 underlying)
  • Conversion

    Series B Preferred Stock

    2014-09-29−1,009,414→ 0 total(indirect: See Footnote)
    → Common Stock (1,009,414 underlying)
  • Conversion

    Common Stock

    2014-09-29+227,117→ 275,450 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+41,270→ 1,265,504 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+48,333→ 48,333 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+9,285→ 284,735 total(indirect: See Footnote)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−3,563→ 0 total(indirect: See Footnote)
    → Common Stock (5,367 underlying)
  • Conversion

    Series B Preferred Stock

    2014-09-29−227,117→ 0 total(indirect: See Footnote)
    → Common Stock (227,117 underlying)
  • Conversion

    Series C Preferred Stock

    2014-09-29−41,270→ 0 total(indirect: See Footnote)
    → Common Stock (41,270 underlying)
VENROCK ASSOCIATES III LP
10% Owner
Transactions
  • Conversion

    Common Stock

    2014-09-29+41,270→ 1,265,504 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+15,446$123,568→ 47,077 total(indirect: See Footnote)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−32,086→ 0 total(indirect: See Footnote)
    → Common Stock (48,333 underlying)
  • Conversion

    Common Stock

    2014-09-29+48,333→ 48,333 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+227,117→ 275,450 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+5,367→ 5,367 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+9,285→ 284,735 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+1,031→ 31,631 total(indirect: See Footnote)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−3,563→ 0 total(indirect: See Footnote)
    → Common Stock (5,367 underlying)
  • Conversion

    Series B Preferred Stock

    2014-09-29−227,117→ 0 total(indirect: See Footnote)
    → Common Stock (227,117 underlying)
  • Conversion

    Common Stock

    2014-09-29+214,820→ 214,820 total(indirect: See Footnote)
  • Conversion

    Series A-2 Preferred Stock

    2014-09-29−142,607→ 0 total(indirect: See Footnote)
    → Common Stock (214,820 underlying)
  • Conversion

    Series C Preferred Stock

    2014-09-29−1,031→ 0 total(indirect: See Footnote)
    → Common Stock (1,031 underlying)
  • Conversion

    Common Stock

    2014-09-29+1,009,414→ 1,224,234 total(indirect: See Footnote)
  • Conversion

    Common Stock

    2014-09-29+25,233→ 30,600 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+617,868$4,942,944→ 1,883,372 total(indirect: See Footnote)
  • Conversion

    Series B Preferred Stock

    2014-09-29−25,233→ 0 total(indirect: See Footnote)
    → Common Stock (25,233 underlying)
  • Conversion

    Series C Preferred Stock

    2014-09-29−9,285→ 0 total(indirect: See Footnote)
    → Common Stock (9,285 underlying)
  • Conversion

    Series C Preferred Stock

    2014-09-29−41,270→ 0 total(indirect: See Footnote)
    → Common Stock (41,270 underlying)
  • Purchase

    Common Stock

    2014-09-29$8.00/sh+139,019$1,112,152→ 423,754 total(indirect: See Footnote)
  • Conversion

    Series B Preferred Stock

    2014-09-29−1,009,414→ 0 total(indirect: See Footnote)
    → Common Stock (1,009,414 underlying)
Footnotes (5)
  • [F1]Each outstanding share of Series A-2 Preferred Stock automatically converted on a 1:1.50638118 basis into the Issuer's common stock, immediately prior to the Issuer's initial public offering, for no additional consideration.
  • [F2]The reportable securities are owned by Venrock Associates.
  • [F3]The reportable securities are owned by Venrock Associates III, L.P. ("VA III"). Venrock Management III, LLC ("VM III") is the general partner of VA III. VM III disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of its pecuniary interest therein.
  • [F4]The reportable securities are owned by Venrock Entrepreneurs Fund III, L.P. ("VEF III"). VEF Management III, LLC ("VEFM III") is the general partner of VEF III. VEFM III disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of its pecuniary interest therein.
  • [F5]Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted on a 1:1 basis into the Issuer's common stock, immediately prior to the Issuer's initial public offering, for no additional consideration.

Documents

1 file

Issuer

Vitae Pharmaceuticals, Inc

CIK 0001157602

→
Entity typeoperating

Related Parties

1
  • filerCIK 0001157602

Filing Metadata

Form type
4
Filed
Sep 30, 8:00 PM ET
Accepted
Oct 1, 4:31 PM ET
Size
52.0 KB
View on SEC.gov